Pharmacological Strategies for Mitigating Anti-TNF Biologic Immunogenicity in Rheumatoid Arthritis Patients

Overview

Journal Curr Opin Pharmacol

Specialty Pharmacology

Date 2022 Dec 29

PMID 36580770

Authors

Christian A Fernandez

Affiliations

Soon will be listed here.

Abstract

Tumor necrosis factor alpha (TNFα) inhibitors are a mainstay of treatment for rheumatoid arthritis (RA) patients after failed responses to conventional disease-modifying antirheumatic drugs (DMARDs). Despite the clinical efficacy of TNFα inhibitors (TNFi), many RA patients experience TNFi treatment failure due to the development of anti-drug antibodies (ADAs) that can neutralize drug levels and lead to RA disease relapse. Methotrexate (MTX) therapy with concomitant TNFα inhibitors decreases the risk of TNFi immunogenicity, but additional and/or alternative strategies are needed to reduce MTX-associated toxicities and to further increase its potency for preventing TNFα inhibitor immunogenicity. In this review, we highlight the limitations of MTX for mitigating TNFα inhibitor immunogenicity, and we discuss potential alternative pharmacological targets for decreasing the risk of immunogenicity during TNFα inhibitor therapy based on the key kinases, second messengers, and shared signaling mechanisms of lymphocyte receptor signaling.

Citing Articles

Quercetin, a Compound of the Total Flavonoids of Schltr., Ameliorates Rheumatoid Arthritis by Targeting TNF-α.

Chen S, Xue W, Wu Z, Lu D, Zheng L, Zhou M J Inflamm Res. 2025; 18:2879-2898.

PMID: 40046683 PMC: 11880692. DOI: 10.2147/JIR.S497166.

Effect of Ozoralizumab Administration with or without Methotrexate in Patients with Rheumatoid Arthritis: A Post-Hoc Analysis.

Tanaka Y, Horiuchi N, Sasajima C, Matsumoto R, Kawanishi M, Uchida S Rheumatol Ther. 2025; .

PMID: 39869270 DOI: 10.1007/s40744-024-00737-3.

Real-World Persistence and Effectiveness of Upadacitinib versus Other Janus Kinase Inhibitors and Tumor Necrosis Factor Inhibitors in Australian Patients with Rheumatoid Arthritis.

Youssef P, Ciciriello S, Tahir T, Leadbetter J, Butcher B, Calao M Rheumatol Ther. 2025; 12(1):173-202.

PMID: 39757285 PMC: 11751354. DOI: 10.1007/s40744-024-00736-4.

Methotrexate Intolerance in Juvenile Idiopathic Arthritis: Definition, Risks, and Management.

Wibrand C, Kyvsgaard N, Herlin T, Glerup M Paediatr Drugs. 2024; 26(5):479-498.

PMID: 39044097 PMC: 11335943. DOI: 10.1007/s40272-024-00643-9.

Adenosine and Its Receptors in the Pathogenesis and Treatment of Inflammatory Skin Diseases.

Chen L, Lei X, Mahnke K Int J Mol Sci. 2024; 25(11).

PMID: 38891997 PMC: 11172165. DOI: 10.3390/ijms25115810.

References

Ogric M, Tercelj M, Praprotnik S, Tomsic M, Bozic B, Sodin-Semrl S . Detection of adalimumab and anti-adalimumab antibodies in patients with rheumatoid arthritis: a comprehensive overview of methodology pitfalls and benefits. Immunol Res. 2016; 65(1):172-185. DOI: 10.1007/s12026-016-8824-8. View

Ying H, Li Z, Yang L, Zhang J . Syk mediates BCR- and CD40-signaling integration during B cell activation. Immunobiology. 2010; 216(5):566-70. PMC: 3075491. DOI: 10.1016/j.imbio.2010.09.016. View

Cronstein B, Aune T . Methotrexate and its mechanisms of action in inflammatory arthritis. Nat Rev Rheumatol. 2020; 16(3):145-154. DOI: 10.1038/s41584-020-0373-9. View

Michaud K, Vrijens B, Tousset E, Pedro S, Schumacher R, Dasic G . Real-World Adherence to Oral Methotrexate Measured Electronically in Patients With Established Rheumatoid Arthritis. ACR Open Rheumatol. 2019; 1(9):560-570. PMC: 6858035. DOI: 10.1002/acr2.11079. View

Mulero M, Aubareda A, Orzaez M, Messeguer J, Serrano-Candelas E, Martinez-Hoyer S . Inhibiting the calcineurin-NFAT (nuclear factor of activated T cells) signaling pathway with a regulator of calcineurin-derived peptide without affecting general calcineurin phosphatase activity. J Biol Chem. 2009; 284(14):9394-401. PMC: 2666591. DOI: 10.1074/jbc.M805889200. View

Wiestner A . Emerging role of kinase-targeted strategies in chronic lymphocytic leukemia. Blood. 2012; 120(24):4684-91. PMC: 3520616. DOI: 10.1182/blood-2012-05-423194. View

Cronstein B . Methotrexate BAFFles anti-drug antibodies. Nat Rev Rheumatol. 2018; 14(9):505-506. DOI: 10.1038/s41584-018-0064-y. View

Stauderman K . CRAC channels as targets for drug discovery and development. Cell Calcium. 2018; 74:147-159. DOI: 10.1016/j.ceca.2018.07.005. View

Park H, Oh K, Garmaa N, Seo M, Byoun O, Lee H . CP-690550, a Janus kinase inhibitor, suppresses CD4+ T-cell-mediated acute graft-versus-host disease by inhibiting the interferon-γ pathway. Transplantation. 2010; 90(8):825-35. DOI: 10.1097/TP.0b013e3181f24e59. View

10.

Bendtzen K, Geborek P, Svenson M, Larsson L, Kapetanovic M, Saxne T . Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab. Arthritis Rheum. 2006; 54(12):3782-9. DOI: 10.1002/art.22214. View

11.

Coqueret O, Boichot E, Lagente V . Selective type IV phosphodiesterase inhibitors prevent IL-4-induced IgE production by human peripheral blood mononuclear cells. Clin Exp Allergy. 1997; 27(7):816-23. View

12.

Li L, Yee C, Beavo J . CD3- and CD28-dependent induction of PDE7 required for T cell activation. Science. 1999; 283(5403):848-51. DOI: 10.1126/science.283.5403.848. View

13.

Nunes A, Raposo C, Luna R, da Cruz-Hofling M, Peixoto C . Sildenafil (Viagra®) down regulates cytokines and prevents demyelination in a cuprizone-induced MS mouse model. Cytokine. 2012; 60(2):540-51. DOI: 10.1016/j.cyto.2012.06.011. View

14.

Gamboa A, Abraham R, Diedrich A, Shibao C, Paranjape S, Farley G . Role of adenosine and nitric oxide on the mechanisms of action of dipyridamole. Stroke. 2005; 36(10):2170-5. DOI: 10.1161/01.STR.0000179044.37760.9d. View

15.

Yu J, Lin G, Field J, Linden J . Induction of antiinflammatory purinergic signaling in activated human iNKT cells. JCI Insight. 2018; 3(17). PMC: 6171811. DOI: 10.1172/jci.insight.91954. View

16.

Welsh S, Corrie P . Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma. Ther Adv Med Oncol. 2015; 7(2):122-36. PMC: 4346212. DOI: 10.1177/1758834014566428. View

17.

Hu J, Jarusiewicz J, Du G, Nishiguchi G, Yoshimura S, Panetta J . Preclinical evaluation of proteolytic targeting of LCK as a therapeutic approach in T cell acute lymphoblastic leukemia. Sci Transl Med. 2022; 14(659):eabo5228. PMC: 9730446. DOI: 10.1126/scitranslmed.abo5228. View

18.

Tan M, Heng T, Mak A . The Potential Use of Metformin, Dipyridamole, N-Acetylcysteine and Statins as Adjunctive Therapy for Systemic Lupus Erythematosus. Cells. 2019; 8(4). PMC: 6523351. DOI: 10.3390/cells8040323. View

19.

Ma X, Xu S . TNF inhibitor therapy for rheumatoid arthritis. Biomed Rep. 2014; 1(2):177-184. PMC: 3956207. DOI: 10.3892/br.2012.42. View

20.

Weinblatt M, Keystone E, Furst D, Moreland L, Weisman M, Birbara C . Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum. 2003; 48(1):35-45. DOI: 10.1002/art.10697. View